期刊文献+

转移性结直肠癌抗EGFR治疗耐药机制研究进展

Review of research progress on mechanism of resistance to anti-EGFR therapy in metastatic colorectal cancer
原文传递
导出
摘要 转移性结直肠癌(mCRC)是结直肠癌进展的晚期阶段,治疗选择多样,但患者预后通常不佳。表皮生长因子受体(EGFR)信号通路在mCRC的发展中扮演核心角色,涉及多个关键分子。EGFR异常活化与肿瘤生长、转移及治疗耐药紧密相关。因此,EGFR靶向治疗对mCRC至关重要,但治疗耐药常常导致治疗失败,且分子机制复杂。在此,笔者综述mCRC抗EGFR治疗耐药的相关分子机制及干预研究进展,为深入理解抗EGFR耐药机制,优化治疗策略提供参考。 Metastatic colorectal cancer(mCRC)represents the advanced stage of colorectal cancer progression.Treatment options are diverse,but patient prognosis is generally poor.The epidermal growth factor receptor(EGFR)signaling pathway plays a central role in the development of mCRC,involving multiple key molecules.Abnormal activation of EGFR is closely related to tumor growth,metastasis,and treatment resistance.Therefore,EGFR-targeted therapy is crucial for mCRC,but treatment resistance often leads to therapy failure,and the molecular mechanisms are complex.Here,the authors review the molecular mechanisms related to anti-EGFR treatment resistance in mCRC and the progress in intervention studies,providing a reference for a deeper understanding of the mechanisms of anti-EGFR resistance and the optimization of treatment strategies.
作者 徐昆明 许云华 陈锡光 付广 黄秋林 肖帅 XU Kunming;XU Yunhua;CHEN Xiguang;FU Guang;HUANG Qiulin;XIAO Shuai(Department of Gastrointestinal Surgery,the First Affiliated Hospital,University of South China,Hengyang,Hunan 421001,China;Cancer Research Institute,the First Affiliated Hospital,University of South China,Hengyang,Hunan 421001,China)
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2024年第6期996-1011,共16页 China Journal of General Surgery
基金 湖南省自然科学基金资助项目(2022JJ30538,2023JJ60368) 湖南省卫生健康委员会科研基金资助项目(20201919,202104010105)。
关键词 结直肠肿瘤 肿瘤转移 ErbB受体 分子靶向治疗 抗药性 肿瘤 综述 Colorectal Neoplasms Neoplasm Metastasis ErbB Receptors Molecular Targeted Therapy Drug Resistance,Neoplasm Review
  • 相关文献

参考文献4

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部